Nicoline Hoogerbrugge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8327038/publications.pdf

Version: 2024-02-01

308 papers	16,840 citations	16451 64 h-index	20358 116 g-index
314 all docs	314 docs citations	314 times ranked	18595 citing authors

#	Article	IF	Citations
1	Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Human Mutation, 2008, 29, 1282-1291.	2.5	782
2	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3â€² exons of TACSTD1. Nature Genetics, 2009, 41, 112-117.	21.4	679
3	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	2.5	513
4	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	3.2	495
5	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
6	Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. British Journal of Cancer, 2009, 100, 266-273.	6.4	392
7	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics, 2005, 42, 711-719.	3.2	360
8	The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clinical Endocrinology, 1992, 37, 79-87.	2.4	328
9	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	21.4	311
10	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
11	Somatic Mutations in MLH1 and MSH2 Are a Frequent Cause of Mismatch-Repair Deficiency in Lynch Syndrome-Like Tumors. Gastroenterology, 2014, 146, 643-646.e8.	1.3	294
12	Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. Journal of Clinical Oncology, 2012, 30, 4409-4415.	1.6	262
13	TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Journal of Medical Genetics, 2010, 47, 421-428.	3.2	254
14	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
15	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	10.7	232
16	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
17	In silico analysis of missense substitutions using sequence-alignment based methods. Human Mutation, 2008, 29, 1327-1336.	2.5	181
18	Lynch Syndrome Caused by Germline PMS2 Mutations: Delineating the Cancer Risk. Journal of Clinical Oncology, 2015, 33, 319-325.	1.6	177

#	Article	IF	Citations
19	Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. American Journal of Human Genetics, 2012, 90, 734-739.	6.2	172
20	Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). Journal of Medical Genetics, 2005, 42, e54-e54.	3.2	170
21	Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Human Mutation, 2008, 29, 1265-1272.	2.5	169
22	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
23	BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 2010, 28, 5265-5273.	1.6	166
24	Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. Journal of Medical Genetics, 2010, 47, 464-470.	3.2	165
25	Cancer Risks for PMS2-Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	1.6	147
26	Health risks for ataxiaâ€telangiectasia mutated heterozygotes: a systematic review, metaâ€analysis and evidenceâ€based guideline. Clinical Genetics, 2016, 90, 105-117.	2.0	143
27	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. European Journal of Human Genetics, 2011, 19, 870-874.	2.8	141
28	Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Human Mutation, 2011, 32, 407-414.	2.5	137
29	High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer. Journal of Clinical Oncology, 2003, 21, 41-45.	1.6	136
30	Hyperglycemia in the acute phase of stroke is not caused by stress.. Stroke, 1993, 24, 1129-1132.	2.0	126
31	Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. European Journal of Medical Genetics, 2016, 59, 116-125.	1.3	125
32	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Research and Treatment, 2009, 116, 479-489.	2.5	124
33	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell, 2019, 35, 256-266.e5.	16.8	123
34	Germline copy number variation and cancer risk. Current Opinion in Genetics and Development, 2010, 20, 282-289.	3.3	115
35	Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting. American Journal of Surgical Pathology, 2008, 32, 1246-1251.	3.7	112
36	CDH1â€related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	5.1	110

#	Article	IF	Citations
37	Prediction and assessment of splicing alterations: implications for clinical testing. Human Mutation, 2008, 29, 1304-1313.	2.5	108
38	Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2004, 22, 3293-3301.	1.6	106
39	EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer, 2013, 12, 169-174.	1.9	100
40	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	2.9	99
41	Revertant Somatic Mosaicism by Mitotic Recombination in Dyskeratosis Congenita. American Journal of Human Genetics, 2012, 90, 426-433.	6.2	97
42	Assessment of functional effects of unclassified genetic variants. Human Mutation, 2008, 29, 1314-1326.	2.5	93
43	Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer, 2006, 94, 814-819.	6.4	90
44	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	2.6	88
45	Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy. Journal of Clinical Oncology, 2002, 20, 2092-2100.	1.6	87
46	Germline Mutations in the Spindle Assembly Checkpoint Genes BUB1 and BUB3 Are Risk Factors for Colorectal Cancer. Gastroenterology, 2013, 145, 544-547.	1.3	86
47	The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Research, 2003, 63, 8153-7.	0.9	86
48	Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia, 2010, 24, 242-246.	7.2	85
49	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	3.5	85
50	Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 109-119.	2.5	83
51	Chromosome 8q23.3 and 11q23.1 Variants Modify Colorectal Cancer Risk in Lynch Syndrome. Gastroenterology, 2009, 136, 131-137.	1.3	80
52	Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Human Mutation, 2008, 29, 1261-1264.	2.5	79
53	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 120, 235-244.	2.5	79
54	Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	2.5	79

#	Article	IF	Citations
55	Cost effectiveness of a new strategy to identify HNPCC patients. Gut, 2005, 54, 97-102.	12.1	78
56	A DGGE system for comprehensive mutation screening ofBRCA1andBRCA2: application in a Dutch cancer clinic setting. Human Mutation, 2006, 27, 654-666.	2.5	75
57	Constitutive expression of Î³-H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology, 2011, 101, 39-45.	0.6	74
58	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics, 2014, 51, 98-107.	3.2	74
59	Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. European Radiology, 2008, 18, 931-938.	4.5	72
60	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71
61	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	1.9	71
62	Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. Gastroenterology, 2015, 149, 897-906.e19.	1.3	70
63	Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. British Journal of Cancer, 2004, 90, 333-342.	6.4	69
64	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	2.9	68
65	Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Scientific Reports, 2015, 5, 14060.	3.3	67
66	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	4.2	67
67	Identification of candidate predisposing copy number variants in familial and earlyâ€onset colorectal cancer patients. International Journal of Cancer, 2011, 129, 1635-1642.	5.1	66
68	Impact ofBRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. American Journal of Medical Genetics Part A, 2004, 124A, 346-355.	2.4	64
69	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	2.5	63
70	Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Familial Cancer, 2009, 8, 391-397.	1.9	63
71	NTHL1 and MUTYH polyposis syndromes: two sides of the same coin?. Journal of Pathology, 2018, 244, 135-142.	4.5	63
72	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European Journal of Human Genetics, 2020, 28, 1387-1393.	2.8	63

#	Article	IF	Citations
73	Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clinical Genetics, 2004, 65, 308-316.	2.0	62
74	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. American Journal of Surgical Pathology, 2004, 28, 706-711.	3.7	62
75	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta OncolÃ³gica, 2016, 55, 1273-1280.	1.8	62
76	Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. Radiology, 2017, 285, 376-388.	7.3	61
77	Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. Leukemia, 1997, 11, 1377-1379.	7.2	60
78	Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. Familial Cancer, 2005, 4, 115-119.	1.9	60
79	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	2.9	60
80	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2011, 126, 193-202.	2.5	59
81	BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics, 2016, 24, 881-888.	2.8	58
82	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	10.7	58
83	A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. BMC Cancer, 2009, 9, 211.	2.6	57
84	Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging. Journal of the National Cancer Institute, 2013, 105, 1314-1321.	6.3	57
85	Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158â†'Cys) Homozygotes Is Associated With Hyperinsulinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 294-299.	2.4	55
86	Identification of germline mutations in the cancer predisposing gene CDH1 in patients with orofacial clefts. Human Molecular Genetics, 2013, 22, 919-926.	2.9	55
87	NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Human Mutation, 2017, 38, 226-235.	2.5	55
88	Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis, 1999, 146, 167-174.	0.8	54
89	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. Human Mutation, 2008, 29, 1292-1303.	2.5	54
90	The decision evaluation scales. Patient Education and Counseling, 2005, 57, 286-293.	2.2	52

#	Article	IF	Citations
91	High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. Clinical Cancer Research, 2018, 24, 1594-1603.	7.0	52
92	Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility. PLoS Genetics, 2016, 12, e1005880.	3.5	52
93	Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. Journal of Medical Genetics, 2005, 42, e20-e20.	3.2	51
94	Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LIPC promoter variant. Diabetes Care, 2003, 26, 427-432.	8.6	50
95	Lynch Syndrome-Associated Extracolonic Tumors Are Rare in Two Extended Families With the Same EPCAM Deletion. American Journal of Gastroenterology, 2011, 106, 1829-1836.	0.4	50
96	Rare variants in XRCC2 as breast cancer susceptibility alleles: TableÂ1. Journal of Medical Genetics, 2012, 49, 618-620.	3.2	49
97	Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. European Journal of Human Genetics, 2021, 29, 1325-1331.	2.8	49
98	Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk. Radiology, 2018, 286, 443-451.	7.3	48
99	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
100	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. Journal of the National Cancer Institute, 2020, 112, 161-169.	6.3	47
101	Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer. Gastroenterology, 2010, 139, 2221-2224.	1.3	46
102	A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2genes based on cancer family history. Breast Cancer Research, 2009, 11, R8.	5.0	45
103	TRIM28 haploinsufficiency predisposes to Wilms tumor. International Journal of Cancer, 2019, 145, 941-951.	5.1	45
104	A review on ageâ€related cancer risks in <scp>PTEN</scp> hamartoma tumor syndrome. Clinical Genetics, 2021, 99, 219-225.	2.0	42
105	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clinical Chemistry, 1997, 43, 1958-1964.	3.2	41
106	Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. British Journal of Cancer, 2007, 96, 1605-1612.	6.4	41
107	Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Human Mutation, 2008, 29, 1273-1281.	2.5	41
108	Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Research and Treatment, 2007, 102, 357-363.	2.5	40

#	Article	IF	Citations
109	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
110	The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Research, 2018, 20, 84.	5.0	40
111	The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. Journal of Internal Medicine, 1990, 228, 261-266.	6.0	37
112	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
113	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Letters, 2017, 403, 159-164.	7.2	37
114	Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. Journal of Medical Genetics, 2018, 55, 669-674.	3.2	37
115	The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Annals of Oncology, 2008, 19, 655-659.	1.2	36
116	Psychosocial impact of Von Hippelâ€“Lindau disease: levels and sources of distress. Clinical Genetics, 2010, 77, 483-491.	2.0	35
117	Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia, 2017, 31, 821-828.	7.2	35
118	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2breast cancer families. Journal of Medical Genetics, 2019, 56, 581-589.	3.2	35
119	Lipoprotein(a) in Patients With Acute Cerebral Ischemia. Stroke, 1996, 27, 1231-1235.	2.0	35
120	Patients with combined hypercholesterolemia-hypertriglyceridemia show an increased monocyte-endothelial cell adhesion in vitro: Triglyceride level as a major determinant. Metabolism: Clinical and Experimental, 1991, 40, 1119-1121.	3.4	34
121	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
122	The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cellular Oncology (Dordrecht), 2016, 39, 491-510.	4.4	34
123	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. European Journal of Human Genetics, 2017, 25, 1246-1252.	2.8	34
124	De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability, Short Stature, and Facial Dysmorphism. American Journal of Human Genetics, 2019, 104, 758-766.	6.2	34
125	The epigenetics of (hereditary) colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 203, 1-6.	1.0	33
126	Noonan syndrome, the SOS1 gene and embryonal rhabdomyosarcoma. Genes Chromosomes and Cancer, 2010, 49, 635-641.	2.8	33

#	Article	IF	Citations
127	Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hereditary Cancer in Clinical Practice, 2012, 10, 18.	1.5	33
128	More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Familial Cancer, 2014, 13, 143-51.	1.9	33
129	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational Oncology, 2019, 12, 361-367.	3.7	33
130	Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. Metabolism: Clinical and Experimental, 1998, 47, 675-680.	3.4	32
131	Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. Diseases of the Colon and Rectum, 2008, 51, 1249-1254.	1.3	32
132	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
133	Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Metabolism: Clinical and Experimental, 1999, 48, 7-14.	3.4	31
134	Chromosome 3 Translocations and Familial Renal Cell Cancer. Current Molecular Medicine, 2004, 4, 849-854.	1.3	31
135	Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping. Clinical Cancer Research, 2006, 12, 1693-1700.	7.0	31
136	BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Critical Reviews in Oncology/Hematology, 2014, 91, 159-171.	4.4	31
137	Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: Patients' and professionals' perspectives. Gynecologic Oncology, 2015, 136, 305-310.	1.4	31
138	Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with earlyâ€onset colorectal cancer. Genes Chromosomes and Cancer, 2016, 55, 855-863.	2.8	30
139	High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCAâ€Mutation Testing without Prior Faceâ€toâ€Face Genetic Counseling. Journal of Genetic Counseling, 2016, 25, 504-514.	1.6	30
140	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. PLoS ONE, 2013, 8, e55734.	2.5	29
141	The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer. Cancer Genetics and Cytogenetics, 2009, 195, 105-111.	1.0	28
142	Germline deletions in the tumour suppressor gene <scp>FOCAD</scp> are associated with polyposis and colorectal cancer development. Journal of Pathology, 2015, 236, 155-164.	4.5	28
143	Low prevalence of serrated polyposis syndrome in screening populations: a systematic review. Endoscopy, 2015, 47, 1043-1049.	1.8	28
144	Cardiovascular risk of BRCA1/2 mutation carriers: A review. Maturitas, 2016, 91, 135-139.	2.4	28

#	Article	IF	Citations
145	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. Gastrointestinal Endoscopy, 2018, 87, 397-404.e2.	1.0	28
146	Atorvastatin, Diabetic Dyslipidemia, and Cognitive Functioning. Diabetes Care, 2002, 25, 1250-1251.	8.6	27
147	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	6.4	27
148	Peritoneal carcinomatosis after riskâ€reducing surgery in BRCA1/2 mutation carriers. Cancer, 2018, 124, 952-959.	4.1	27
149	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers. JAMA Oncology, 2021, 7, 1203.	7.1	27
150	Numerous high-risk epithelial lesions in familial breast cancer. European Journal of Cancer, 2006, 42, 2492-2498.	2.8	26
151	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. BMC Genomics, 2007, 8, 299.	2.8	26
152	In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology, 2009, 55, 414-422.	2.9	26
153	Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. Annals of Oncology, 2014, 25, 2001-2007.	1.2	26
154	HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 673-679.	2.8	26
155	Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. Arthritis Research and Therapy, 2019, 21, 50.	3.5	25
156	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2022, 40, 1879-1891.	1.6	25
157	Hypertriglyceridemia Enhances Monocyte Binding to Endothelial Cells in NIDDM. Diabetes Care, 1996, 19, 1122-1125.	8.6	24
158	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24
159	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	2.5	23
160	Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress. Clinical Genetics, 2015, 87, 319-326.	2.0	23
161	Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. Gynecologic Oncology, 2016, 143, 113-119.	1.4	23
162	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. American Journal of Human Genetics, 2022, 109, 953-960.	6.2	23

#	Article	IF	Citations
163	Monocytes from patients with combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia show an increased adhesion to endothelial cells in vitro: II. Influence of intrinsic and extrinsic factors on monocyte binding. Metabolism: Clinical and Experimental, 1995, 44, 374-378.	3.4	22
164	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). European Journal of Human Genetics, 2013, 21, 891-891.	2.8	22
165	How medical choices influence quality of life of women carrying a BRCA mutation. Critical Reviews in Oncology/Hematology, 2015, 96, 555-568.	4.4	22
166	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
167	Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. European Journal of Human Genetics, 2020, 28, 277-286.	2.8	22
168	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. European Journal of Medical Genetics, 2021, 64, 104350.	1.3	22
169	Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women. Journal of Endocrinology, 1989, 123, 341-345.	2.6	21
170	Mapping of constitutional translocation breakpoints in renal cell cancer patients: identification of KCNIP4 as a candidate gene. Cancer Genetics and Cytogenetics, 2007, 179, 11-18.	1.0	21
171	Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2. European Journal of Human Genetics, 2009, 17, 159-164.	2.8	21
172	Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. Journal of Medical Genetics, 2014, 51, 55-60.	3.2	21
173	Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers. Obstetrics and Gynecology, 2016, 127, 1054-1063.	2.4	21
174	European Reference Networks: challenges and opportunities. Journal of Community Genetics, 2021, 12, 217-229.	1.2	21
175	NTHL1 defines novel cancer syndrome. Oncotarget, 2015, 6, 34069-34070.	1.8	21
176	Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. Clinical Genetics, 2003, 63, 64-70.	2.0	20
177	Colorectal Cancer Risk in Patients With Lynch Syndrome andÂInflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 454-458.e1.	4.4	20
178	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). European Journal of Human Genetics, 2018, 26, 1417-1423.	2.8	20
179	Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. Oncogene, 2019, 38, 3743-3755.	5.9	20
180	Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. Gastroenterology, 2020, 159, 2241-2243.e6.	1.3	20

#	Article	IF	Citations
181	Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. Colorectal Disease, 2013, 15, e175-85; discussion p.e185.	1.4	19
182	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	3.8	18
183	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. European Journal of Radiology, 2013, 82, 1416-1422.	2.6	18
184	â€œPatient Journeysâ€: improving care by patient involvement. European Journal of Human Genetics, 2020, 28, 141-143.	2.8	18
185	Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact. Familial Cancer, 2009, 8, 325-337.	1.9	17
186	Plasma pre Î²-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 714-718.	2.4	17
187	Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 653-659.	2.8	17
188	A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Research and Treatment, 2011, 130, 425-436.	2.5	17
189	Poor prognosis of constitutive Î³-H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	1.4	17
190	A patient decision aid for riskâ€reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing. Health Expectations, 2018, 21, 659-667.	2.6	17
191	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. Familial Cancer, 2019, 18, 281-284.	1.9	17
192	Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress. Genetic Counseling, 2010, 21, 423-37.	0.1	17
193	Genomeâ€wide linkage scan in Dutch hereditary nonâ€BRCA1/2 breast cancer families identifies 9q21â€22 as a putative breast cancer susceptibility locus. Genes Chromosomes and Cancer, 2008, 47, 947-956.	2.8	16
194	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
195	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologistâ€™s initiative. Familial Cancer, 2012, 11, 259-267.	1.9	16
196	Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition. British Journal of Cancer, 2017, 116, 163-168.	6.4	16
197	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. Journal of Internal Medicine, 1998, 244, 143-147.	6.0	15
198	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	6.4	15

#	Article	IF	Citations
199	Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2Âyears. Familial Cancer, 2010, 9, 213-220.	1.9	15
200	Can we test for hereditary cancer at 18Âyears when we start surveillance at 25? Patient reported outcomes. Familial Cancer, 2013, 12, 675-682.	1.9	15
201	Finding all BRCA pathogenic mutation carriers: best practice models. European Journal of Human Genetics, 2016, 24, S19-S26.	2.8	15
202	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	2.4	15
203	Evaluation of yield and experiences of ageâ€related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome. International Journal of Cancer, 2020, 147, 2150-2158.	5.1	15
204	Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism: Clinical and Experimental, 1996, 45, 680-685.	3.4	14
205	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. BMC Women's Health, 2011, 11, 39.	2.0	14
206	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Familial Cancer, 2015, 14, 89-94.	1.9	14
207	Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress. European Journal of Cancer, 2017, 78, 45-52.	2.8	14
208	Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome. European Thyroid Journal, 2020, 9, 234-242.	2.4	14
209	Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of â€˜easy to applyâ€™ probability models. British Journal of Cancer, 2006, 95, 757-762.	6.4	13
210	Spindle-Assembly Checkpoint and Gastrointestinal Cancer. New England Journal of Medicine, 2011, 364, 1279-1280.	27.0	13
211	Relevance and efficacy of breast cancer screening inBRCA1andBRCA2mutation carriers above 60 years: A national cohort study. International Journal of Cancer, 2014, 135, 2940-2949.	5.1	13
212	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	1.9	13
213	Somatic Nonepigenetic Mismatch Repair Gene Aberrations Underly Most Mismatch Repairâ€“Deficient Lynch-Like Tumors. Gastroenterology, 2021, 160, 1414-1416.e3.	1.3	13
214	Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability. British Journal of Cancer, 2006, 95, 1678-1682.	6.4	12
215	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	2.5	12
216	Adequacy of family history taking in ovarian cancer patients: a population-based study. Familial Cancer, 2012, 11, 343-349.	1.9	12

#	Article	IF	Citations
217	Easyâ€toâ€use online referral test detects most patients with a high familial risk of colorectal cancer. Colorectal Disease, 2014, 16, O26-34.	1.4	12
218	A molecular inversion probe-based next-generation sequencing panel to detect germline mutations in Chinese early-onset colorectal cancer patients. Oncotarget, 2017, 8, 24533-24547.	1.8	12
219	The IGF-I/IGFBP system in congenital partial lipodystrophy. Clinical Endocrinology, 1998, 49, 465-473.	2.4	11
220	High fat intake in hyperlipidaemic patients is related to male gender, smoking, alcohol intake and obesity. Netherlands Journal of Medicine, 2001, 59, 16-22.	0.5	11
221	Is early-onset microsatellite and chromosomally stable colorectal cancer a hallmark of a genetic susceptibility syndrome?. International Journal of Cancer, 2008, 122, 796-801.	5.1	11
222	Predisposition to colorectal cancer: exploiting copy number variation to identify novel predisposing genes and mechanisms. Cytogenetic and Genome Research, 2008, 123, 188-194.	1.1	11
223	Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. European Journal of Cancer, 2011, 47, 1407-1413.	2.8	11
224	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	2.5	11
225	Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists. Clinical Nurse Specialist, 2015, 29, E1-E7.	0.5	11
226	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	7.1	11
227	Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. Gynecologic Oncology, 2022, 164, 221-230.	1.4	11
228	A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy. International Journal of Gynecological Cancer, 2006, 16, 1940-1944.	2.5	10
229	Unfavorable pathological characteristics in familial colorectal cancer with low-level microsatellite instability. Modern Pathology, 2006, 19, 1624-1630.	5.5	10
230	Focusing on Patient Needs and Preferences May Improve Genetic Counseling for Colorectal Cancer. Journal of Genetic Counseling, 2013, 22, 118-124.	1.6	10
231	Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases. World Journal of Gastroenterology, 2015, 21, 4136.	3.3	10
232	Improving recognition and referral of patients with an increased familial risk of colorectal cancer: results from a randomized controlled trial. Colorectal Disease, 2015, 17, 499-510.	1.4	10
233	RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps. Histopathology, 2021, 78, 749-758.	2.9	10
234	Determinants of adherence to recommendations for cancer prevention among Lynch Syndrome mutation carriers: A qualitative exploration. PLoS ONE, 2017, 12, e0178205.	2.5	10

#	Article	IF	Citations
235	Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. European Journal of Medical Genetics, 2022, 65, 104401.	1.3	10
236	Growth hormone and thyroxine affect lipoprotein metabolism in hypothyroid and hypophysectomized rats. Journal of Endocrinology, 1990, 125, 403-407.	2.6	9
237	Corneal arcus: indicator for severity of coronary atherosclerosis?. Netherlands Journal of Medicine, 1999, 55, 184-187.	0.5	9
238	Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for a randomized controlled trial. Implementation Science, 2010, 5, 6.	6.9	9
239	DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Women's Health, 2012, 12, 12.	2.0	9
240	Increasing awareness and knowledge of lifestyle recommendations for cancer prevention in Lynch syndrome carriers: Randomized controlled trial. Clinical Genetics, 2018, 93, 67-77.	2.0	9
241	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. European Journal of Human Genetics, 2021, 29, 1354-1358.	2.8	9
242	Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. Genetic Counseling, 2003, 14, 149-54.	0.1	9
243	Genetic testing offered directly after the diagnosis of colorectal cancer: a pilot study on the reactions of patients. Genetic Counseling, 2009, 20, 317-25.	0.1	9
244	Gemfibrozil decreases autoantibodies against oxidized lowâ€density lipoprotein in men with combined hyperlipidaemia. Journal of Internal Medicine, 1998, 243, 355-359.	6.0	8
245	Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 25-29.	2.8	8
246	Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress. Familial Cancer, 2011, 10, 51-57.	1.9	8
247	Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers. Familial Cancer, 2016, 15, 563-570.	1.9	8
248	Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening. European Journal of Cancer, 2011, 47, 1571-1577.	2.8	7
249	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	6.4	7
250	High demoralization in a minority of oophorectomized BRCA1/2 mutation carriers influences quality of life. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 96-104.	2.1	7
251	Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromesâ€“Considerations for Future Studies. International Journal of Molecular Sciences, 2020, 21, 8757.	4.1	7
252	Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome. European Journal of Medical Genetics, 2021, 64, 104364.	1.3	7

#	Article	IF	Citations
253	LETTERS TO THE EDITOR. Journal of Internal Medicine, 1995, 237, 603-605.	6.0	6
254	Growth hormone restores hepatic lipase mRNA levels but the translation is impaired in hepatocytes of hypothyroid rats. Lipids and Lipid Metabolism, 1997, 1345, 172-179.	2.6	6
255	The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. Journal of Internal Medicine, 2002, 251, 148-155.	6.0	6
256	Optimizing the detection of hereditary non-polyposis colorectal cancer: An update. Scandinavian Journal of Gastroenterology, 2006, 41, 146-152.	1.5	6
257	Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. Journal of Clinical Epidemiology, 2011, 64, 1434-1443.	5.0	6
258	A multiplex method for the detection of serum antibodies against in silico-predicted tumor antigens. Cancer Immunology, Immunotherapy, 2014, 63, 1251-1259.	4.2	6
259	Lifestyle Risk Factors for Breast Cancer in BRCA1/2â€Mutation Carriers Around Childbearing Age. Journal of Genetic Counseling, 2017, 26, 785-791.	1.6	6
260	Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling. Acta OncolÃ³gica, 2019, 58, 175-181.	1.8	6
261	Growth hormone normalizes hepatic lipase in hypothyroid rat liver. Metabolism: Clinical and Experimental, 1993, 42, 669-671.	3.4	5
262	Easy-to-Use Decision Aids for Improved Cancer Family History Collection and Use Among Oncology Practices. Journal of Clinical Oncology, 2014, 32, 3343-3343.	1.6	5
263	Peer support and additional information in group medical consultations (GMCs) forBRCA1/2mutation carriers: A randomized controlled trial. Acta OncolÃ³gica, 2016, 55, 178-187.	1.8	5
264	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. Clinical Chemistry, 1997, 43, 1958-64.	3.2	5
265	Reliability of self-reported diagnostic radiation history in BRCA1/2Âmutation carriers. European Journal of Epidemiology, 2010, 25, 103-113.	5.7	4
266	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431.	2.8	4
267	Added Value of Family History in Counseling About Risk of BRCA1/2 Mutation in Early-Onset Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2013, 23, 1406-1410.	2.5	4
268	Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma. Hereditary Cancer in Clinical Practice, 2014, 12, 21.	1.5	4
269	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. Annals of Oncology, 2016, 27, vi362.	1.2	4
270	Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review. European Journal of Medical Genetics, 2022, , 104533.	1.3	4

#	Article	IF	Citations
271	The yield and effectiveness of breast cancer surveillance in women with <scp>PTEN</scp> Hamartoma Tumor Syndrome. Cancer, 2022, 128, 2883-2891.	4.1	4
272	Incidence of cancer in first-degree relatives of basal cell carcinoma patients. Archives of Dermatological Research, 2009, 301, 295-299.	1.9	3
273	Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers. Maturitas, 2018, 108, 13-17.	2.4	3
274	No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Journal of Cardiology, 2021, 77, 570-575.	1.9	3
275	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345.	3.7	3
276	Healthcare professionalsâ€™ perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups. Familial Cancer, 2023, 22, 1-11.	1.9	3
277	An online selfâ€test added to colorectal cancer screening can increase the effectiveness of familial cancer risk assessment without increasing distress. Colorectal Disease, 2018, 20, 897-904.	1.4	2
278	Continue rare cancers collaboration with European Reference Networks after Brexit. Lancet, The, 2021, 397, 793.	13.7	2
279	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. Gynecologic Oncology, 2021, 163, 371-377.	1.4	2
280	Familial Breast Cancer: Detection of Prevalent High-Risk Epithelial Lesions. , 2008, , 61-71.		2
281	Genetic Cancer Susceptibility in Adolescents and Adults 25ÂYears or Younger With Colorectal Cancer. Gastroenterology, 2022, 162, 969-974.e6.	1.3	2
282	Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects. Magnesium Research, 1996, 9, 129-32.	0.5	2
283	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€“ a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	1.3	2
284	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Journal of Internal Medicine, 1997, 241, 151-155.	6.0	1
285	Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?. British Journal of Cancer, 2006, 95, 1126-1127.	6.4	1
286	Germline epimutation of the tumor suppressor gene PTPRJ in early onset familial colorectal cancer. Cancer Genetics and Cytogenetics, 2010, 203, 59.	1.0	1
287	Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors. Familial Cancer, 2012, 11, 19-26.	1.9	1
288	Comparability versus statistical correctness. European Journal of Radiology, 2013, 82, e908.	2.6	1

#	Article	IF	Citations
289	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-Tumor Phenotype Including a Predisposition to Colon and Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	1
290	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. Supportive Care in Cancer, 2022, 30, 3409-3418.	2.2	1
291	Detecting Lynch syndrome by pathologists. Verhandlungen Der Deutschen Gesellschaft FÃ¼r Pathologie, 2007, 91, 104-11.	0.5	1
292	Hypertension treatment with doxazosin significantly decreases femoral wall thickness in males with hypercholesterolemia and peripheral atherosclerotic disease. Atherosclerosis, 1999, 144, 129-130.	0.8	0
293	High saturated fat intake in hyperlipidemic patients is related to male gender, smoking, alcohol intake and obesity. Atherosclerosis, 1999, 144, 130.	0.8	0
294	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. Breast Cancer Research, 2005, 7, 1.	5.0	0
295	Costs of breast cancer surveillance in BRCA mutation carriers. European Journal of Cancer, Supplement, 2008, 6, 94-95.	2.2	0
296	Constitutional submicroscopic genome imbalances in children with both cancer and a congenital anomaly. Cancer Genetics and Cytogenetics, 2010, 203, 52.	1.0	0
297	EPCAM deletions and heritable MSH2 promoter methylation in Lynch syndrome. Cancer Genetics and Cytogenetics, 2010, 203, 57.	1.0	0
298	PP 73 Prognostic relevance of constitutive expression of Î³-H2AX in triple negative breast cancers. European Journal of Cancer, 2011, 47, S25.	2.8	0
299	Erfelijke darmkanker. Bijblijven (Amsterdam, Netherlands), 2011, 27, 20-26.	0.0	0
300	Highlights from the seventh European Multidisciplinary Colorectal Cancer Congress (EMCCC) 2014. Ecancermedicalscience, 2015, 9, 497.	1.1	0
301	Self-compassion and climacteric symptoms in postmenopausal BRCA1/2 mutation carriers. Maturitas, 2017, 100, 130.	2.4	0
302	Response to Tomao, Panici, and Tomao. Journal of the National Cancer Institute, 2020, 112, 425-425.	6.3	0
303	Breast cancer surveillance in women with PTEN Hamartoma Tumour Syndrome (PHTS). Breast, 2021, 56, S38.	2.2	0
304	Universal genetic assessment for women with ovarian cancer not yet achieved: the promises of universal tumor DNA testing. Gynecologic Oncology Reports, 2021, 38, 100825.	0.6	0
305	9 Genetisch is profetisch?. , 2012, , 91-99.		0
306	Abstract P3-02-09: Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition. , 2012, , .		0

#	Article	IF	Citations
307	Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome. , 2016, , .		0
308	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Journal of Internal Medicine, 1997, 241, 151-5.	6.0	0